Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) has been assigned an average broker rating score of 1.00 (Strong Buy) from the two analysts that cover the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Brokers have set a 12 month consensus price target of $40.00 for the company and are expecting that the company will post ($0.44) EPS for the current quarter, according to Zacks. Zacks has also assigned Bellicum Pharmaceuticals an industry rank of 61 out of 265 based on the ratings given to its competitors.
BLCM has been the subject of a number of research analyst reports. Guggenheim raised shares of Bellicum Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $38.00 price target for the company in a research report on Friday, September 11th. Piper Jaffray reissued a “buy” rating on shares of Bellicum Pharmaceuticals in a research report on Tuesday, September 8th. Jefferies Group reissued a “buy” rating and issued a $35.00 price target on shares of Bellicum Pharmaceuticals in a research report on Tuesday, December 8th. Finally, Zacks Investment Research lowered shares of Bellicum Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, December 14th.
In other news, insider David M. Spencer sold 5,000 shares of the firm’s stock in a transaction on Tuesday, December 1st. The shares were sold at an average price of $22.95, for a total value of $114,750.00. Following the sale, the insider now owns 178,600 shares in the company, valued at $4,098,870. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO Alan A. Musso sold 29,300 shares of the firm’s stock in a transaction on Tuesday, November 24th. The stock was sold at an average price of $22.34, for a total transaction of $654,562.00. Following the completion of the sale, the chief financial officer now owns 88,742 shares in the company, valued at approximately $1,982,496.28. The disclosure for this sale can be found here.
Bellicum Pharmaceuticals (NASDAQ:BLCM) opened at 19.92 on Monday. The stock has a 50 day moving average of $20.64 and a 200 day moving average of $18.49. The stock’s market capitalization is $527.90 million. Bellicum Pharmaceuticals has a 52 week low of $12.25 and a 52 week high of $33.63.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.13. During the same period last year, the business earned ($2.08) earnings per share. The firm had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.18 million. Bellicum Pharmaceuticals’s quarterly revenue was down 90.9% compared to the same quarter last year. On average, equities research analysts predict that Bellicum Pharmaceuticals will post ($1.64) earnings per share for the current fiscal year.
Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its chemical induction of dimerization (NASDAQ:BLCM) technology platform to engineer and then control components of the immune system in real time. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy, and dendritic cell vaccines. The Company’s product candidates include BPX-501, BPX-201, BPX-401, BPX-601 and BPX-701. It is also engaged in other development programs, such as CIDeCAR for the treatment of solid tumors and CaspaCIDe TCR for the treatment of hematological cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com